Fig. 5
Ex vivo imaging following FME indicated that lesion detection during endoscopy in L2-IL1B/IL8Tg mice was PARPi-FL specific. A Ex vivo wide-field fluorescence images of excised stomachs from PARPi-FL-injected and non-injected mice that underwent FME. The SCJ is marked by dotted lines, while black arrows indicate the lesions. Only in PARPi-FL-injected mice, lesions in the brightfield (BF) were also visible in the FITC channel (arrows and close up images). B Confocal microscopy of the SCJ of the same mice confirmed nuclear PARPi-FL uptake. C Quantification of single lesions plotted per Tukey’s method with outliers and line at the median (left) and mean TBR per mouse (center) in PARPi-FL-injected mice by ex vivo wide-field imaging with mean ± SEM. ** p < 0.01 and **** p < 0.0001 by one-way ANOVA followed by Tukey’s test. D Mean fluorescence intensities (MFI) in macroscopically visible lesions measured in ex vivo wide-field imaging comparing non-injected with PARPi-FL injected mice. The horizontal line represented the mean MFI of PBS-injected mice. * p < 0.05 and **** p < 0.0001 by one way ANOVA followed by Tukey’s test. E Quantification of confocal microscopy analysis of sections at the SCJ of PARPi-FL-injected mice according to the dysplasia grade. No significant difference in PARPi-FL signal between dysplasia grade 2 and 3 was found (p = 0.149). Data are plotted as single values per each field and mean ± SEM (grade 0–1 = 1 mouse; grade 2 = 4 mice; grade 3 = 5 mice)